Sarepta Therapeutics Inc (BSP:S1RP34)
R$ 37.72 -0.52 (-1.36%) Market Cap: 72.06 Bil Enterprise Value: 73.29 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 79/100

Sarepta Therapeutics Inc at TD Cowen RNA Therapeutics Summit (Virtual) Transcript

Jul 10, 2023 / 03:00PM GMT
Release Date Price: R$26.58 (+0.11%)
Ritu Subhalaksmi Baral
TD Cowen, Research Division - MD & Senior Biotechnology Analyst

Hi, everyone. Thanks for joining us today for the Sarepta fireside chat at TD Cowen's Second Annual RNA Therapeutics Summit. With us for the fireside chat, we have Sarepta's CEO, Doug Ingram. Also on the line if we need him, we have CFO, Ian Estepan.

Thank you so much, Doug, for joining us today. Busy times for you guys, but I did want to take the time today to focus on what is really your foundational technology from back in the day and the foundation for base business, the PMO and PPMO DMD therapies. There's been a lot of discussion about your newly approved DMD gene therapy, ELEVIDYS certainly. But then it turns to what will become of your close to $1 billion DMD PMO franchise and your PPMO pipeline for DMD going forward.

So Doug, let's start on a high level. What are the aspects of AAV gene therapies as you see it, that you think RNA therapies, particularly your PPMOs could address?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot